324 related articles for article (PubMed ID: 32019731)
1. Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center.
Soekojo CY; Low JZ; Oh J; Ooi M; De Mel S; Chng WJ
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):e165-e170. PubMed ID: 32019731
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.
Drayson MT; Bowcock S; Planche T; Iqbal G; Pratt G; Yong K; Wood J; Raynes K; Higgins H; Dawkins B; Meads D; Hulme CT; Whittaker AC; Hawkey P; Low E; Dunn JA
Health Technol Assess; 2019 Nov; 23(62):1-94. PubMed ID: 31690402
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.
Bici A; Pianko MJ; Nachar VR
Leuk Lymphoma; 2023 Feb; 64(2):407-414. PubMed ID: 36308285
[TBL] [Abstract][Full Text] [Related]
4. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic prophylaxis and the gastrointestinal resistome in paediatric patients with acute lymphoblastic leukaemia: a cohort study with metagenomic sequencing analysis.
Margolis EB; Hakim H; Dallas RH; Allison KJ; Ferrolino J; Sun Y; Pui CH; Yao J; Chang TC; Hayden RT; Jeha S; Tuomanen EI; Tang L; Rosch JW; Wolf J
Lancet Microbe; 2021 Apr; 2(4):e159-e167. PubMed ID: 34355208
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
8. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
9. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.
Wolf J; Tang L; Flynn PM; Pui CH; Gaur AH; Sun Y; Inaba H; Stewart T; Hayden RT; Hakim H; Jeha S
Clin Infect Dis; 2017 Nov; 65(11):1790-1798. PubMed ID: 29020310
[TBL] [Abstract][Full Text] [Related]
11. Oral trimethoprim/sulfamethoxazole for prevention of bacterial infection during the induction phase of cancer chemotherapy in children.
Kovatch AL; Wald ER; Albo VC; Prin W; Orlando SJ; Wollman MR; Phebus CK; Shapiro ED
Pediatrics; 1985 Nov; 76(5):754-60. PubMed ID: 3903647
[TBL] [Abstract][Full Text] [Related]
12. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.
Vesole DH; Oken MM; Heckler C; Greipp PR; Katz MS; Jacobus S; Morrow GR;
Leukemia; 2012 Dec; 26(12):2517-20. PubMed ID: 22678167
[TBL] [Abstract][Full Text] [Related]
13. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
[No Abstract] [Full Text] [Related]
14. Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.
Mayer K; Hahn-Ast C; Mückter S; Schmitz A; Krause S; Felder L; Bekeredjian-Ding I; Molitor E; Brossart P; von Lilienfeld-Toal M
Support Care Cancer; 2015 May; 23(5):1321-9. PubMed ID: 25617073
[TBL] [Abstract][Full Text] [Related]
15. Infections during induction therapy for children with acute lymphoblastic leukemia. the role of sulfamethoxazole-trimethoprim (SMX-TMP) prophylaxis.
Rungoe C; Malchau EL; Larsen LN; Schroeder H
Pediatr Blood Cancer; 2010 Aug; 55(2):304-8. PubMed ID: 20583218
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia.
Schrøder H; Agger KE; Rosthøj S; Carlsen NT; Schmiegelow K
Dan Med Bull; 2001 Nov; 48(4):275-7. PubMed ID: 11767129
[TBL] [Abstract][Full Text] [Related]
18. [Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during induction therapy of children with acute lymphatic leukemia].
Agger KE; Schrøder H; Rosthøj S; Carlsen NT; Schmiegelow K
Ugeskr Laeger; 2002 Jan; 164(4):488-92. PubMed ID: 11838420
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
20. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
Lu J; Lu J; Liu A; Fu W; Du J; Huang X; Chen W; Hou J
Biomed Res Int; 2015; 2015():856704. PubMed ID: 26640799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]